Handa Pharmaceuticals (ROCO:6620) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
75 GF Score
Price NT$84.70
GF Value NT$183.95
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Handa Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


ROCO:6620 vs ZTS, UTHR: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Handa Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Handa Pharmaceuticals's Short Interest falls into.


ROCO:6620
75GF Score
Handa Pharmaceuticals Inc ROCO:6620
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$84.70 is trading 54% below its estimated GF Value™ of NT$183.95. GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ROCO:6620:

  • Short Interest:
  • GF Value™: NT$183.95 vs. price of NT$84.70 (54% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score

Get the complete analysis for ROCO:6620

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$84.70
Price
NT$183.95
GF Value